Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* Patient has a diagnosis of IBS by Rome III criteria with a subtype of diarrhea~* Female patients must be:~* postmenopausal, defined as amenorrhea for at least 2 years at Prescreening,~* surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy),~* abstinent, or~* if sexually active, be practicing an effective method of birth control.~Key Exclusion Criteria:~* Patient has a diagnosis of IBS by Rome III criteria with a subtype of constipation, mixed IBS, or unsubtyped IBS~* Patient has a history of inflammatory or immune-mediated gastrointestinal (GI) disorders including inflammatory bowel disease (ie, Crohn's disease, ulcerative colitis) and celiac disease~* Patient has a history of diverticulitis within 6 months prior to Prescreening~* Patient has a history of intestinal obstruction, stricture, toxic megacolon, GI perforation, fecal impaction, gastric banding, bariatric surgery, adhesions, ischemic colitis, impaired intestinal circulation (eg, aortoiliac disease), thrombophlebitis of a major vein, or hypercoagulable states.~Other protocol-specific eligibility criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Eluxadoline 5 mg (Type: EXPERIMENTAL): Eluxadoline 5 mg tablets, orally, twice daily for up to 12 weeks.
- Eluxadoline 25 mg (Type: EXPERIMENTAL): Eluxadoline 25 mg tablets, orally, twice daily for up to 12 weeks. .
- Eluxadoline 100 mg (Type: EXPERIMENTAL): Eluxadoline 100 mg tablets, orally, twice daily for up to 12 weeks.
- Eluxadoline 200 mg (Type: EXPERIMENTAL): Eluxadoline 200 mg tablets, orally, twice daily for up to 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Eluxadoline placebo matching tablets, orally, twice daily for up to 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).